A Single-arm, Open-label, Multi-center, Phase IV Trial to Evaluate the Reactogenicity, Safety, and Immunogenicity of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India

The purpose of this study is to gather additional evidence of the safety and immunogenicity of 1 dose of Fluarix Tetra (0.5 milliliter [mL]) (Northern Hemisphere (NH)2023-2024) in individuals aged 65 years and above to fulfill a post-approval condition imposed by the Indian regulatory authorities (CDSCO) for this age group in India.

Start Date14 Dec 2023

Sponsor / Collaborator

GSK Plc

NCT05734040

/ CompletedPhase 2

Phase 2a, Randomized, Double-blind (Double-dummy), Double Placebo-controlled, Parallel-group Study to Evaluate the Immunogenicity and the Safety of the Concomitant Administration of OVX836 Influenza Vaccine and Quadrivalent Inactivated Influenza Vaccines (QIVs: Fluarix Tetra and Afluria Quad) Given Intramuscularly as 2 Separate Injections Into Opposite Arms, in Comparison to the Concomitant Administration of Quadrivalent Inactivated Influenza Vaccines and Placebo, and OVX836 and Placebo Given the Same Way in Healthy Subjects Aged 18 to 60 Years.

The present study OVX836-006 aims principally to:
* Confirm feasibility of the concomitant administration of the vaccines under normal clinical conditions, i.e. as two separate concomitant injections into opposite arms;
* Introduce an additional representative brand of Quadrivalent Inactivated Influenza Vaccines ;
* Demonstrate the absence of interaction between OVX836 and Quadrivalent Inactivated Influenza Vaccines on the Hemagglutinin response;
* Demonstrate the absence of interaction between OVX836 and Quadrivalent Inactivated Influenza Vaccines on the nucleoprotein response;
* Evaluate the absolute vaccine efficacy of OVX836 compared to placebo in order to corroborate the efficacy signals previously detected in the OVX836 previous studies;
* Evaluate the combined vaccine efficacy of OVX836 + Quadrivalent Inactivated Influenza Vaccines versus OVX836 + placebo, and versus double placebo.

Start Date10 May 2023

Sponsor / Collaborator

Osivax SAS

[+2]

CTRI/2022/12/048070

/ CompletedPhase 4

A single-arm, open-label, multi-center, phase IV trial to evaluate the reactogenicity, safety, and immunogenicity of quadrivalent seasonal influenza vaccine (Fluarix Tetra) in participants aged 65 years and older in India

Start Date20 Dec 2022

Sponsor / Collaborator

GlaxoSmithKline Biologicals SA

[+1]

100 Clinical Results associated with Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

100 Translational Medicine associated with Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

100 Patents (Medical) associated with Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

150

Literatures (Medical) associated with Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

31 Dec 2026·Human Vaccines & Immunotherapeutics

Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study

Article

Author: Leroux-Roels, Isabel ; Langley, Joanne M. ; Knauer, Christine ; Mesia Vela, Doris ; Ovbude, Leroy Jide ; Borobia, Alberto M. ; Moldt, Brian ; Srivastava, Barkha ; Koch, Sven D. ; Ruiz-Antorán, Belén ; Nordgren, Marcus ; Ochoa Mazarro, Dolores ; Pardo, Iris Alessandra ; Germain, Sophie ; De Coster, Ilse ; Berrè, Stefano ; Mann, Philipp

This first-in-human, randomized, controlled, phase 1 proof-of-principle study evaluated the safety, reactogenicity, and immunogenicity of an investigational mRNA-based monovalent influenza vaccine encoding influenza A/H1N1 hemagglutinin (FLUmHA). Younger adults (YA) aged 18-45 y received one dose of FLUmHA at one of 10 dose levels (0.5-100 µg, n = 24/25 per group) or licensed Flu Dresden-quadrivalent seasonal influenza vaccine (Flu D-QIV, n = 35) on day (D)1. Older adults (OA) aged 60-80 y received FLUmHA (18 µg, n = 32) or Flu D-QIV (n = 16). Reporting rates for solicited adverse events (AEs) occurring within 7 d post-vaccination generally increased with increasing FLUmHA dose levels, and were 62.5%-100% (severe: 0.0%-20.8%) in YA across FLUmHA dose levels versus 88.6% (severe: 2.9%) in Flu D-QIV-vaccinated YA, and 62.5% (severe: 0.0%) (FLUmHA) versus 56.3% (severe: 0.0%) (Flu D-QIV) in OA. Unsolicited AEs within 28 d post-vaccination were reported by 50.0%-70.8% of YA across FLUmHA dose levels versus 68.6% of Flu D-QIV-vaccinated YA, and by 43.8% (FLUmHA) versus 50.0% (Flu D-QIV) of OA. No safety concerns were identified. A/H1N1 hemagglutination inhibition titers increased from pre-vaccination to D22, with adjusted geometric mean increases (GMIs) of 6.2-36.7 across YA and OA groups; the observed response was dose-dependent and higher in FLUmHA (for doses > 1 µg) versus Flu D-QIV recipients. Titers decreased but remained above pre-vaccination levels at D183 (GMI: 2.9-14.0). Additionally, FLUmHA elicited a numerically higher hemagglutinin-specific CD4+ T-cell response (predominantly Th1 profile) than Flu D-QIV, both in YA and OA. These results support the progression to clinical development of a multivalent mRNA Flu vaccine candidate.Trial registration: NCT05446740.

01 May 2026·VACCINE

Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study

Article

Author: Folegatti, Pedro M ; See, Stephanie ; Kaas-Leach, Kathleen ; Tabar, Cynthia ; Pepin, Stephanie ; De Bruijn, Iris ; Talanova, Oxana ; Fries, Katherine

Influenza vaccines for those aged <9 years old are limited to the standard-dose inactivated influenza vaccine (IIV) and live-attenuated intranasal influenza vaccine. In this Phase III, modified double-blind, active-controlled trial, participants aged 3-8 years were randomised in a 1:1 ratio to receive the quadrivalent recombinant influenza vaccine (RIV4) or quadrivalent inactivated influenza vaccine (IIV4). The non-inferiority of immune responses was assessed using geometric mean titre ratios (GMTRs) 28 days after the last vaccine administration and seroconversion rates (NCT05513391). A futility analysis was conducted after approximately 25% of the overall sample size was enrolled. Of the 1412 participants planned, 366 participants were enrolled in the United States, Poland, and Spain, resulting in a lower overall study power. The RIV4 induced non-inferior immune responses to those for IIV4 for the A/H1N1, A/H3N2, and B/Yamagata strains but not for the B/Victoria strain. Both vaccines were well tolerated with no safety concerns.

01 Feb 2026·VACCINE

Immunogenicity of mRNA COVID-19 vaccine with either simultaneous or sequentially administered inactivated influenza vaccines: a randomized clinical trial

Article

Author: Walter, Emmanuel B ; Davis, Grace N ; Broder, Karen R ; Montefiori, David ; Schlaudecker, Elizabeth P ; Spreng, Rachel L ; Rountree, Wes ; Tekalign, Rediet ; Poniewierski, Marek S ; Goel, Anju ; Schmader, Kenneth E ; Staat, Mary A ; Talaat, Kawsar R ; Museru, Oidda ; Duffy, Jonathan

BACKGROUND:

A U.S. multisite trial was conducted and explored whether blunting of mRNA COVID-19 vaccine immunogenicity occurred when administered simultaneously with influenza vaccine.

METHODS:

Persons ≥5 years of age received either quadrivalent inactivated influenza vaccine (IIV4) or saline placebo simultaneously with an initial or booster dose of mRNA COVID-19 vaccine. Those receiving placebo with mRNA COVID-19 vaccine received IIV4 7-14 days later. SARS-CoV-2 antibody was assessed by pseudovirus neutralization (D614G, BA.4/BA. 5, and XBB.1.5) at baseline and 28 days following mRNA COVID-19 vaccine primary series or booster dose.

RESULTS:

Of 335 randomized participants, 157 were in the simultaneous group and 150 the sequential group. Post-vaccination geometric mean SARS-CoV-2 ID50 titers for the ancestral D614G strain and BA.4/5 variant (simultaneous versus sequential) were 4357.1 versus 4492.3(p = 0.79) and 1547.8 versus 1463.8(p = 0.69), respectively.

CONCLUSION:

Blunting of mRNA COVID-19 vaccine immunogenicity was not observed when mRNA COVID-19 and influenza vaccines were administered simultaneously. TRIAL REGISTRATIONClinicalTrials.gov ID: NCT05028361.

News (Medical) associated with Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

06 Aug 2026

·firstwordpharma.com

FDA approves Moderna's mRNA flu vaccine after months of regulatory turmoil

Moderna, reeling under a recent late-stage setback to its norovirus vaccine programme, finally has some good news to celebrate. After a winding regulatory battle, the FDA authorised the company's influenza vaccine mFlusiva (mRNA-1010) for use in all adults aged 50 years and older. The product is slated to hit the shelves in the coming weeks, ahead of the 2026–2027 respiratory virus season."Our fourth approved product in the US and the first mRNA-based flu vaccine, demonstrates the continued strength and versatility of our mRNA platform," said CEO Stéphane Bancel. "Flu remains a significant public health challenge, and mFlusiva provides an important new option for America's seniors."mFlusiva now joins Moderna's diverse respiratory vaccine portfolio, which includes COVID-19 shots Spikevax and mNexspike, and RSV vaccine mResvia.The traditional approval of mFlusiva for adults aged 50 through 64 years was supported by a global Phase III trial of over 40,000 participants, wherein mFlusiva achieved a relative vaccine efficacy against influenza illness of 26.6% versus GSK's Fluarix, the standard-dose active comparator.Meanwhile, the mRNA flu vaccine secured accelerated approval in adults aged 65 and older based on a separate trial enrolling 2,992 US adults in this age bracket, pitting it against a high-dose inactivated influenza vaccine comparator. Confirmation of clinical benefit in this population will be evaluated through a 400,000-participant post-marketing study in this cohort.Story so far..mFlusiva's regulatory journey was anything but straightforward. In February this year, the FDA's Center for Biologics Evaluation and Research (CBER) issued a refusal-to-file letter, declining to review the marketing application for the vaccine despite Moderna's use of a priority review voucher. The letter, signed by then-CBER director Vinay Prasad, raised no safety or efficacy concerns but objected to the company's use of a licensed seasonal flu vaccine as its Phase III comparator. While Moderna dubbed the decision "inconsistent" with earlier feedback, the FDA's then-commissioner Marty Makary countered that the company had ignored "very clear" agency guidance.The stand-off, however, was short-lived. Another meeting shortly followed — reportedly under pressure from the White House — and the regulator agreed to accept the application, setting a target action date of August 5. Amid this, Prasad announced he would step down from CBER for a second time following a string of contentious decisions on vaccines and gene therapies.An FDA advisory committee (adcom) meeting was scheduled for June 18, and briefing documents released ahead found no major deficiencies with mFlusiva's application, sending Moderna's shares up more than 6% at the time. The agency staff, however, did flag evidence gaps in immunocompromised and frail older populations, and noted that pivotal trial data covered only a single flu season. At the adcom, panel members voted 9-0 in favour of mFlusiva, praising the vaccine's immunogenicity data and its potential to elicit stronger T-cell responses than existing flu shots, while urging the company to ensure its large post-marketing trial addresses remaining uncertainties in high-risk populations.Regulatory submissions for the Moderna vaccine also remain under review in the EU, Canada and Australia, with additional filings planned during the year.mRNA under fireThe Department of Health and Human Services has repeatedly raised unsubstantiated safety concerns regarding mRNA vaccines, and last August cancelled about $500 million in funding for 22 mRNA vaccine programmes.The increased scrutiny of mRNA vaccines prompted Moderna to withdraw its FDA application for influenza/COVID-19 combination vaccine mRNA-1083 last year after regulators sought additional Phase III flu efficacy data. The filing had been intended to follow the review of mFlusiva.Meanwhile, Pfizer too is developing a standalone mRNA influenza vaccine — which showed favourable Phase III efficacy data — in addition to an influenza/COVID-19 combination vaccine in collaboration with BioNTech.

Phase 3VaccineDrug ApprovalmRNAClinical Result

03 Aug 2026

·www.pharmaindustrial-india.com

GSK India Reports 24 Percent PAT Growth in Q1 FY27

GlaxoSmithKline (GSK) Pharmaceuticals has announced its financial results for the first quarter ended June 30, 2026. During the quarter, the company delivered strong growth across both its core and innovative portfolios. The performance reflects continued progress in the company's portfolio transformation strategy, supplemented by execution excellence, and a favorable base effect from the comparable period last year. Revenue for the quarter stood at INR 924 crore, up 15 percent Year-on-Year (YoY). Profit After Tax (PAT) increased by 24 percent to INR 253 crore, while EBITDA margins stood at 32 percent. The General Medicines portfolio grew strongly during the quarter, with the top 5 promoted brands outperforming the market (EI* >100; Source: IQVIA). Key promoted brands such as Augmentin, Ceftum and T-Bact reinforced their leadership positions in their respective categories, driven by a combination of deeper scientific and in-clinic engagement, omnichannel execution, and pricing measures. The Respiratory portfolio continued to further the management of chronic respiratory diseases with Nucala (mepolizumab) benefitting a large number of patients and Trelegy Ellipta gaining traction through new access pathways. The vaccines business grew through continued leadership in the self-pay private pediatric vaccines market, led by Infanrix Hexa and Fluarix Tetra. In the adult vaccination space, the company’s focus on elderly patient-cohorts with underlying Cardiovascular and Metabolic Diseases (CVMD) led to stronger endorsement from the healthcare professional community, translating to higher vaccinations with Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted). The oncology business, led by specialised therapies Jemperli (dostarlimab) and Zejula (niraparib), has grown significantly since its launch in August last year. Jemperli is now the leading immunotherapy for first line primary advanced and recurrent endometrial cancer while Zejula is among the top PARP inhibitors in the maintenance treatment of recurrent ovarian cancer. Together, both therapies have touched the lives of a growing number of women suffering from gynecological malignancies, with GSK committed to expanding access and patient reach. Commenting on the results, Bhushan Akshikar, Managing Director (MD), GSK India, said, "GSK India's broad-based growth demonstrates the resilience of the core General Medicines and Vaccines portfolio and the growing contribution of the innovative business. This growth was enabled by a relentless focus on scientific excellence, sharper execution in the field and meaningful investments in technology and talent development. With a strong innovation pipeline and launch opportunities ahead, we are well-positioned to deliver sustainable growth and meaningful impact for millions of patients in India." The company has made progress in strengthening supply chain resilience through diversified sourcing, enhanced contingency planning and improved end-to-end visibility, substantially mitigating disruptions experienced in recent quarters. Looking ahead, GSK India is preparing for key pipeline launches. Blenrep (belantamab mafodotin), an anti-BCMA ADC therapy indicated for second-line treatment in relapsed or refractory multiple myeloma in adults, is set for launch. Arexvy, a vaccine to prevent Lower Respiratory Tract Disease (LRTD) caused by Respiratory Syncytial Virus (RSV) in adults over 60 years of age and older adults (50 to 59 years) at high-risk, has received Marketing Authorisation (MA).

VaccineDrug ApprovalFinancial Statement

21 Apr 2026

·www.biospace.com

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19

mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized product mCOMBRIAX will be made available in the European Union, subject to national regulatory and access procedures CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mCOMBRIAX ® (mRNA-1083), the Company's mRNA combination vaccine for active immunization for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older. This marketing authorization follows the positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and is valid in all 27 European Union member states, as well as Iceland, Liechtenstein and Norway. mCOMBRIAX is Moderna's fourth authorized product, further strengthening the Company's respiratory portfolio and commitment to the European Union. "We welcome the European Commission's approval of mCOMBRIAX, the world's first flu plus COVID-19 combination vaccine," said Stéphane Bancel, Chief Executive Officer of Moderna. "By combining protection against two significant respiratory viruses in a single dose, our vaccine aims to simplify immunization for adults, particularly those at high risk. mCOMBRIAX offers an important new option for Europeans, while also aiming to strengthen the resilience of healthcare systems across Europe." mCOMBRIAX builds on the advances from the clinical development of mNEXSPIKE ® , Moderna's COVID-19 vaccine, and mRNA-1010 , Moderna's investigational seasonal influenza vaccine, which has been accepted for review in the European Union, United States, Canada and Australia. The EC's authorization is based on the results from the pivotal Phase 3 clinical trial (ClinicalTrials.gov Identifier: NCT06097273 ), a randomized, observer-blind, active-controlled study evaluating the safety, reactogenicity, and immunogenicity of mRNA-1083 in two independent age cohorts of approximately 4,000 adults each. One cohort included adults 65 years of age and older and compared mRNA-1083 to co-administered Fluzone HD ® (licensed in the European Union as Efluelda ® ), a high-dose influenza vaccine, and Spikevax ® , Moderna's licensed COVID-19 vaccine. The second cohort included adults 50 to 64 years of age and compared mRNA-1083 to co-administered Fluarix ® , a standard-dose influenza vaccine, and Spikevax. All primary endpoints demonstrating the non-inferiority of immune responses were met. Following a single dose, mRNA-1083 elicited statistically significantly higher immune responses against three influenza virus strains (A/H1N1, A/H3N2, and B/Victoria) and against SARS-CoV-2 in both age cohorts. The B/Yamagata strain, which is no longer recommended for inclusion in seasonal influenza vaccines, was the only strain for which a statistically significantly higher immune response was not observed for adults 65 years of age and older compared to the co-administered licensed comparator vaccines. [1] mRNA-1083 demonstrated an acceptable safety and tolerability profile. The majority of solicited adverse reactions were grade 1 or 2 in severity and consistent with the licensed vaccines used in the trial. mCOMBRIAX will be made available across the European Union, subject to national regulatory and access procedures, with Moderna working closely with national authorities to support local access and implementation. About Moderna Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn. mCOMBRIAX ® , mNEXSPIKE ® and Spikevax ® are registered trademarks of Moderna. Fluzone HD ® and Efluelda ® are registered trademarks of Sanofi Pasteur. Fluarix ® is a registered trademark of the GlaxoSmithKline group of companies. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the availability of mCOMBRIAX in Europe, subject to national regulatory and access procedures; Moderna's work with national authorities to support local access and implementation; the potential of combination vaccines to simplify vaccination and support improved health outcomes; ongoing regulatory review of mRNA-1010 in several jurisdictions, and the potential for approval; and the safety, reactogenicity and immunogenicity of mRNA-1083. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Global: Chris Ridley Vice President, Global Head of Communications +1 617-800-3651 Chris.Ridley@modernatx.com EU: Clothilde Caillet Director, Country and Europe Communications Lead (+33) 07 60 87 68 72 Clothilde.caillet@modernatx.com Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 Lavina.Talukdar@modernatx.com [1] Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years: A Randomized Clinical Trial. JAMA: The Journal of the American Medical Association, published online 7 May 2025, SOURCE : Moderna, Inc. View the original press release on ACCESS Newswire

VaccineDrug ApprovalClinical ResultPhase 3mRNA

100 Deals associated with Influenza virus vaccine, quadrivalent(GlaxoSmithKline Plc)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BB02	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Influenza, Human	Australia	GSK Plc	28 Aug 2013
Influenza A virus infection	United States	GlaxoSmithKline Biologicals SA	31 Aug 2005
Influenza B virus infection	United States	GlaxoSmithKline Biologicals SA	31 Aug 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05648357 (Pubmed \| Hum Vaccin Immunother)	Phase 4	Influenza, Human	250	Fluarix Tetra	mfeqmwwsoc(qxxscfyaiq) = rhhtiyhbtu ubjkdvxpni (lciqvwdvng ) View more	Positive	31 Dec 2025
NCT05648357 (CTgov)	Phase 4	Influenza, Human	250	Fluarix Tetra Vaccine	hlqqsavmzm = ppzpvkqkaf zsvjiumigh (lslymksqef, qxqcauteqo - xwvmqiovix) View more	-	28 Mar 2025
NCT05047770 (Pubmed) Manual	Phase 3	Herpes Zoster	497	mRNA-1273quFlu D-QIVt influenza vaccine (QIV)	zazsmoxuvx(pbllnpvuqe) = The most frequently reported adverse events in both groups were pain at the injection site and myalgia. blgcxuznxd (axnoezehwe ) View more	Non-inferior	31 Dec 2024
				mRNA-1273 + Flu D-QIV(CoAd )
NCT03722589 (CTgov)	Phase 4	Influenza, Human	944	Flublok (Flublok (Recombinant))	deyntloxci = wrhmyyejtn rcsburmcky (umtpmmysst, iblwtsgpku - ggqmqbuxwy) View more	-	22 Jul 2024
				Flucelvax (Flucelvax (Cell-based))	deyntloxci = priizlxivx rcsburmcky (umtpmmysst, mzzfiiqypq - irwydbovyd) View more
NCT05045144 \| EUCTR2021-000357-26-ES (Pubmed)	Phase 3	-	1,415	RSVPreF3 vaccine lot 1	cyjkdlrmin(qinyymodrj) = Co-administration was well tolerated, and both vaccines had clinically acceptable safety and reactogenicity profiles tcpnvuhrcy (pjxwjxwfup )	Positive	05 Jul 2024
				RSVPreF3 vaccine lot 2
NCT02707692 (CTgov)	Not Applicable	Acquired Immunodeficiency Syndrome	54	placebo+Pneumovax-23 (Pneumococcal Vaccine)	guqbfpsbtu(vyselowywe) = bfebrrquny khcedwxflu (czyzotveae, 2998.0)	-	24 Aug 2022
				Fluarix+placebo (Influenza Vaccine)	guqbfpsbtu(vyselowywe) = krbmilimim khcedwxflu (czyzotveae, 243.2) View more
NCT03686514 (FLU2, CTgov)	Phase 4	Influenza, Human	39	seasonal influenza vaccine (H3N2 Birth Cohort, Born Between 1968 and 1977)	jfukwjtcwn = gctgibubap ohnkretyhe (pubefecmnu, qaiqrnpyuh - hkytrcherm) View more	-	13 Jul 2022
				seasonal influenza vaccine (H1N1 Birth Cohort, Born Between 1948 and 1957)	jfukwjtcwn = ownmtnzijw ohnkretyhe (pubefecmnu, rlbphytpby - nhzodhzdrz) View more
NCT03701061 (HIPCVAX-010S, CTgov)	Phase 4	influenza A subtype H5N1 infection	12	Seasonal Influenza Vaccine (Participants That Received AS03 Adjuvant)	kgegypcnfj = choxevisgq pusrifdqvy (ieuapjgtwf, gwmpxgyzli - rzyrhjyjtt) View more	-	11 Mar 2020
				Seasonal Influenza Vaccine (Participants That Did Not Receive AS03 Adjuvant)	kgegypcnfj = izecyfsilu pusrifdqvy (ieuapjgtwf, lskfrvzpkv - kaadlzkhpg) View more
NCT01439360 (Pubmed \| Pediatr Infect Dis J)	Phase 3	Influenza, Human	12,046	Inactivated Quadrivalent Influenza Vaccine (IIV4)	kgytvchewf(ymoutrqhhf) = 46% less frequent following vaccination with IIV4 than with control skxjylzsze (xvhrzvfafs ) View more	-	01 Aug 2019
				Inactivated Quadrivalent Influenza Vaccine (Control)
NCT03165981 (CTgov)	Phase 4	Seizures, Febrile \| Fever \| Vaccination	221	IIV+DTaP+PCV13 (Simultaneous Vaccination Arm)	kjmakflphq = fhwsrsaeus jlrsczgnve (ptvoteqtqq, xxwfgjpiyn - lhkbsjdxem) View more	-	08 Feb 2019
				IIV+DTaP+PCV13 (Sequential Vaccination Arm)	kjmakflphq = qaogrbdsid jlrsczgnve (ptvoteqtqq, kkkazcjsol - tpkduteoqc) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis